Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;20(10):1969-1977.
doi: 10.2174/1570159X20666220302153123.

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Mengjuan Xing  1 , Jialing Sheng  2 , Mengxin Cui  3 , Yousong Su  1 , Chengfang Zhang  4 , Xi Chen  1   5 , Yu Fang  1   5 , Donghong Cui  1   5   6 , Zezhi Li  7   8
Affiliations

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Mengjuan Xing et al. Curr Neuropharmacol. 2022.

Abstract

Background: Antipsychotics are known to be associated with metabolic syndromes (MetS). Chlorpromazine (CPZ) and Clozapine (CLZ) are currently the most commonly used antipsychotics in low-income districts of China. However, potential differences in the long-term effects of CPZ and CLZ on MetS in schizophrenia inpatients are not well understood. Here, we aimed to identify any MetS profile differences between long-term schizophrenia patients who were prescribed either CPZ or CLZ at a primary psychiatric hospital.

Methods: We recruited a total of 204 male schizophrenia patients who received either CPZ or CLZ. We measured their weight, height, body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), and systolic blood pressure (SBP), as well as their biochemical indicators, including fasting blood glucose (FBS), triglycerides (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c).

Results: The MetS prevalence in the CPZ and CLZ groups was 31% and 37.5%, respectively. The CLZ group had significantly higher DBP levels and a higher incidence of dyslipidemia (HDL-c) but lower HDL-c and TC levels than the CPZ group. We also determined that smoking history, BMI, and duration of hospitalisation were risk factors for the development of MetS. Moreover, we found that CPZ and CLZ were correlated with the same risk for developing MetS and that BMI was a vital risk factor of MetS for both the CPZ and CLZ groups.

Conclusion: Long-term CPZ and CLZ prescriptions were associated with similar profiles for developing MetS of schizophrenia patients.

Keywords: Schizophrenia; antipsychotics; diabetes; dyslipidemia; metabolic syndrome; retrospective cohort study.

PubMed Disclaimer

References

    1. Thornicroft G. Premature death among people with mental illness. BMJ. 2013;346:f2969. doi: 10.1136/bmj.f2969. - DOI - PubMed
    1. Laursen T.M., Nordentoft M., Mortensen P.B. Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol. 2014;10:425–448. doi: 10.1146/annurev-clinpsy-032813-153657. - DOI - PubMed
    1. Correll C.U., Solmi M., Veronese N., Bortolato B., Rosson S., Santonastaso P., Thapa-Chhetri N., Fornaro M., Gallicchio D., Collantoni E., Pigato G., Favaro A., Monaco F., Kohler C., Vancampfort D., Ward P.B., Gaughran F., Carvalho A.F., Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180. doi: 10.1002/wps.20420. - DOI - PMC - PubMed
    1. Tune J.D., Goodwill A.G., Sassoon D.J., Mather K.J. Cardiovascular consequences of metabolic syndrome. Transl. Res. 2017;183:57–70. doi: 10.1016/j.trsl.2017.01.001. - DOI - PMC - PubMed
    1. Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P., Rinfret S., Schiffrin E.L., Eisenberg M.J. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010;56(14):1113–1132. doi: 10.1016/j.jacc.2010.05.034. - DOI - PubMed